Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rezolute, Inc.

NASDAQ: RZLT · Life Sciences · 7 alerts · CIK 1509261

Rezolute, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.58Close, Nov 16
Market cap
$346M
Shares outstanding
96.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗

4:18 PM ET 8-K
Financial Results

Rezolute Financial Results

Rezolute, Inc. reported financial results for its first fiscal quarter ended September 30, 2026, ending the period with $90.0 million in cash and investments. The company provided clinical updates on its ersodetug program, noting that enrollment is complete for the Phase 3 upLIFT study in tumor HI with topline results expected in December 2026, and plans to submit a BLA for one or both HI indications in 2027.

Term
Q1 2027
4:17 PM ET 8-K
Financial Results

Rezolute Financial Results

Rezolute, Inc. reported its financial results for the fourth quarter and full fiscal year ended June 30, 2026. The company highlighted clinical progress in its Phase 3 upLIFT study for tumor hyperinsulinism (HI), with topline results expected by the end of 2026, while its Phase 3 sunRIZE study in congenital HI remains under FDA review after failing to meet its primary endpoint.

Term
FY2026

“The past year was marked by significant progress across our clinical programs, particularly with the positive interim data from our upLIFT study in tumor HI. We remain focused on completing enrollment and delivering topline results as we work toward providing a potential new treatment option for patients suffering from refractory hypoglycemia.”

Nevan Charles Elam, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.